Patent intelligence · US
US 12404313
GDNF fusion polypeptides and methods of use thereof
GDNF fusion polypeptides and methods of use thereof
Patent details — US 12404313
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 2, 2025
- Expiration
- Aug 28, 2045
- Applicant
- Keros Therapeutics, Inc.
- Claims
- 15
- CPC classes
- A61K, A61K38/00, A61P, A61P25/00
Quick answer
US 12404313 (GDNF fusion polypeptides and methods of use thereof) is held by Keros Therapeutics, Inc.. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Keros Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K38/00, A61P, A61P25/00, A61P3/00, A61P3/04
More from Keros Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12364737
Activin receptor type IIA variants and methods of use thereof
granted -
US 12350313
Activin receptor type IIa variants and methods of use thereof
granted -
US 12331124
ALK2 antibodies and methods of use thereof
granted -
US 12269858
Activin receptor type IIB variants and methods of use thereof
granted -
US 12071438
Crystal forms of an ALK2 inhibitor
granted -
US 11912750
GDNF fusion polypeptides and methods of use thereof
granted -
US 11884715
Activin receptor type IIB variants and methods of use thereof
granted
Frequently asked questions
What is US patent 12404313?
US 12404313 (GDNF fusion polypeptides and methods of use thereof) is held by Keros Therapeutics, Inc.. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12404313?
Keros Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 12404313 expire?
Our index shows an expiration date of Aug 28, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.